CCL5 and atherosclerosis: Research has demonstrated that both antagonism and deficiency of the CCR5/CCL5-axis attenuate atherosclerosis in advanced stages by decreasing lesion size, promoting plaque stability, and reducing monocyte, macrophage, and T cell infiltration [67, 68].